Zidovudine
FDA Approved
Description
Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI) used in the treatment of HTLV-1 infection and associated conditions. While primarily developed for HIV, it has shown efficacy in managing HTLV-1-related diseases including infective dermatitis. It is often used in combination with other antiretroviral agents for HTLV-1-associated conditions.
Indications & Therapeutic Use
HIV infection, HTLV-1 infection, infective dermatitis associated with HTLV-1
Linked Diseases:
Global Availability (7 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Zidovudine
| Generic Name | Zidovudine |
| Brands | 1 brand available |
| Active Ingredient | Zidovudine |
| Drug Class | HIV infection |
| Manufacturer | ViiV Healthcare |
| Dosage Forms | Oral capsule 100mg; Oral syrup 50mg/5mL; IV infusion 10mg/mL |
| Medical Code | J05AF01 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00000625 |
| Countries | 7 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations8 Validated Nodes